(23.01.2024) On Wednesday 7 February, Oxford Biomedica, a quality and innovation-led cell and gene therapy CDMO, will host a free 60-minute webinar offering Read More
(07.12.2023) Oxford Biomedica has made significant progress in its streamlining of operations to become a pure-play quality and innovation-led global cell and gene therapy CDMO. The Company has concluded Read More
– Oxford Biomedica announces the signing of a sale and purchase agreement with Institut Mérieux for the acquisition of ABL Europe – The transaction: Provides Oxford Biomedica with multi viral vector CDMO capabilities – to be made available across the Company’s six manufacturing sites in EU, US and UK… Read More
Newly appointed Chief Executive Officer, Dr. Frank Mathias, is leading a transformation to position Oxford Biomedica as a pure-play CDMO; strategic and operational streamlining ongoing Transformation into a pure-play CDMO by 1 January 2024, with £30 million of annualised costs savings Strong execution and delivery of commercial strategy evidenced by… Read More
Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation The Proposed Transaction, would: Provide Oxford Biomedica multi viral vector CDMO capabilities across multiple sites in EU, US and UK… Read More
Oxford, UK – 07 September 2023: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces that it will host a webinar on the TetraVecta™ system, the Company’s 4th generation lentiviral vector delivery system, on Monday 2 October 2023. The webinar… Read More
Oxford, UK – 22 August 2023: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces that it has expanded its License and Supply Agreement (“LSA”) with Cabaletta Bio, Inc. (Nasdaq: CABA) (“Cabaletta Bio”), a Philadelphia-based clinical-stage biotechnology company focused on… Read More
Oxford Biomedica launches the TetraVectaTM – the next generation lentiviral vector system Oxford, UK – 15 May 2023: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces the launch of its 4th generation lentiviral vector delivery system, TetraVectaTM. This state-of-the-art technology… Read More
London, UK – 5 May 2023: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica”, “the Company” or “the Group”), a quality and innovation-led viral vector CDMO, gives notice that the Notice of Annual General Meeting (“AGM”) together with a copy of the 2022 Annual report and accounts are… Read More
London, UK – 28 April 2023: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica”, “the Company” or “the Group”), a quality and innovation-led viral vector CDMO, gives notice that the 2022 Annual report and accounts is now available on the “Investors” section of the Group’s website at www.oxb.com. In accordance with… Read More
Oxford, UK – 26th April 2023: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces the appointment of Ms Leone Patterson as an Independent Non-Executive Director. Ms Patterson shall join the Board on 1st May 2023. Ms Patterson has more than… Read More
Enhancing our position as a global quality and innovation-led viral vector CDMO Oxford, UK – 25 April 2023: Oxford Biomedica plc (“Oxford Biomedica” or “the Company”) (LSE: Oxford Biomedica), a quality and innovation-led viral vector CDMO, announces its preliminary results for the year ended 31 December 2022. Dr. Frank Mathias, Oxford… Read More